Latest news with #PfizerInc.
Yahoo
29-05-2025
- Business
- Yahoo
Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F
This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to growth during the historic period can be attributed to an aging population, the launch of vaccination programs, increased awareness of respiratory illnesses, government health initiatives, and seasonal respiratory illness outbreaks. Major companies operating in the abrysvo or arexvy market are Pfizer Inc. and GlaxoSmithKline plc (GSK). North America was the largest region in the abrysvo or arexvy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast during the market's forecast period can be attributed to the expanding elderly population, increased vaccine access and global distribution, a greater emphasis on preventative healthcare, a rising incidence of respiratory infections, and improved healthcare policies and coverage. Key trends in the forecast period include advancements in vaccine technology, personalized medicine, integration of wearable health technology, innovations in vaccine delivery, cold chain logistics, and smart growing prevalence of respiratory syncytial virus (RSV) infections is expected to drive the growth of the abrysvo or arexvy market in the future. RSV infections are caused by the respiratory syncytial virus, a common virus that primarily affects the respiratory system, leading to mild cold-like symptoms in most individuals, but potentially severe illness in infants, older adults, and those with weakened immune systems. The increasing prevalence of RSV infections is fueled by the virus's highly contagious nature, seasonal outbreaks, lack of widespread immunity, and heightened vulnerability among populations such as infants and the elderly. Abrysvo helps address this issue by providing targeted vaccines to protect high-risk groups, such as older adults and infants, from severe RSV-related illnesses. For example, in October 2024, the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, reported that during the 2024-25 season, the hospitalization rate for RSV was 3.2 per 100,000 individuals. As a result, the rising prevalence of RSV infections is driving the growth of the abrysvo or arexvy increase in healthcare expenditure is also expected to support the growth of the abrysvo or arexvy market. Healthcare expenditure refers to the financial investment made by governments, private insurers, and individuals into the healthcare system to enhance and expand medical services. This rise in healthcare expenditure is driven by factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, a higher demand for healthcare services, and rising costs of pharmaceuticals and treatments. Increased healthcare spending provides more financial resources for advanced treatment options, including biologic therapies, which benefits the Abrysvo or Arexvy market. For instance, in May 2023, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. The total healthcare expenditure in the UK amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditure is contributing to the growth of the abrysvo or arexvy market.A key trend in the abrysvo or arexvy market is the expansion of age indications to extend the vaccine's use to a broader range of age groups, thereby enhancing public health protection and increasing market reach. The bivalent RSV prefusion F (RSVpreF) vaccine is designed to provide immunity against respiratory syncytial virus (RSV), targeting both the RSV-A and RSV-B subtypes. For example, in October 2024, Pfizer Inc., a US-based pharmaceutical company, received FDA approval for ABRYSVO (RSV Vaccine), a bivalent RSVpreF vaccine, to prevent lower respiratory tract disease in adults aged 18 to 59 at increased risk, thus broadening its indication to a wider adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 Topics Covered: 1. Executive Summary2. Abrysvo or Arexvy Market Characteristics3. Abrysvo or Arexvy Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Abrysvo or Arexvy Market Trends and Strategies5. Abrysvo or Arexvy Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Abrysvo or Arexvy Growth Analysis and Strategic Analysis Framework6.1. Global Abrysvo or Arexvy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Abrysvo or Arexvy Market Growth Rate Analysis6.4. Global Abrysvo or Arexvy Historic Market Size and Growth, 2019-2024, Value ($ Million)6.5. Global Abrysvo or Arexvy Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)6.6. Global Abrysvo or Arexvy Total Addressable Market (TAM)7. Global Abrysvo or Arexvy Pricing Analysis & Forecasts8. Abrysvo or Arexvy Market Segmentation8.1. Global Abrysvo or Arexvy Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Respiratory Syncytial Virus (RSV) Prevention Infant Protection 8.2. Global Abrysvo or Arexvy Market, Segmentation by Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Adults (18-59 years) Older Adults (60+ years) Pregnant Individuals (32-36 weeks of gestation) 8.3. Global Abrysvo or Arexvy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Healthcare Providers Pregnant Individuals High-Risk Adults 9. Global Abrysvo or Arexvy Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Abrysvo or Arexvy Market Regional and Country Analysis10.1. Global Abrysvo or Arexvy Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million10.2. Global Abrysvo or Arexvy Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ MillionCompanies Featured Pfizer Inc. GlaxoSmithKline plc (GSK) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-05-2025
- Business
- Yahoo
Pharmaceutical Drugs Industry and Competition Analysis, Forecast to 2029 - AI, Nanotech, and 3D Printing Among Key Disruptors Shaping the Future of Pharmaceutical Drug Development
Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Drugs Industry: Competitive Landscape 2023" report has been added to Pharmaceutical Drugs Market was valued at USD 1.6 Trillion in 2024, and is projected to reach USD 2.2 Trillion by 2029, rising at a CAGR of 5.5%. This report discusses the global pharmaceutical drugs industry and its competitive landscape in terms of significant player market ranking and top pharmaceutical drugs. Company profiles of the top 50 pharmaceutical companies, innovative products and technologies, trends and market dynamics, competitive intelligence, and regional trends are well-researched and analyzed in this research report analyzes the global market for pharmaceutical drugs and its competitive landscape through 2029. It covers leading manufacturers of pharmaceutical drugs and the companies providing pharmaceutical services to biopharma and pharmaceutical firms), competitive intelligence and technological advances. The analysis includes recent developments in the product portfolios of major companies, as well as market share and rankings. The regulatory landscape analysis focuses on recent regulations in the U.S., Europe, and Japan. The analyst estimated market size data for 2023 (base year) and forecast values for 2024 through the end of 2029. This report also examines drivers, restraints, and opportunities in the global report includes: 57 data tables and 152 additional tables Evaluation of the current and future market potential of the pharmaceutical industry, featuring a look at the competitive landscape of the 50 leading pharmaceutical manufacturers Analyses of the global market trends, with historical market revenue data (sales figures) from 2021-2024, and projected CAGRs through 2029 Discussion of the opportunities in the pharmaceutical industry, along with an evaluation of the competitive environment, regulatory landscape, and technological trends and advances A look at the regulatory and pricing scenarios in the global market, with an emphasis on recently enacted regulations in the U.S., Europe and Japan Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies Analysis of patent activity, including key granted and published patents Descriptive company profiles of the leading pharma manufacturers, including: Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., and F. Hoffmann La Roche Ltd. Key Attributes Report Attribute Details No. of Pages 272 Forecast Period 2024-2029 Estimated Market Value (USD) in 2024 $1.6 Trillion Forecasted Market Value (USD) by 2029 $2.2 Trillion Compound Annual Growth Rate 5.5% Regions Covered Global Key Topics CoveredChapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Overview Stakeholders Involved in the Innovation Process Future Perspectives PESTEL Analysis Porter's Five Forces Analysis Supply Chain Analysis Raw Materials Sourcing Drug Manufacturing QC and Compliance Distribution Regulatory Approval and Pricing Constraints Sales and Marketing Reverse Logistics and Returns Chapter 3 Market Dynamics Market Dynamics Market Drivers Rising Healthcare Expenditures Focus on Rare Diseases and Orphan Drugs Increasing Prevalence of Chronic Diseases and Aging Populations Market Restraints Stringent Regulatory Concerns Loss of Exclusivity and Genericization Lack of Oncology Professionals Market Opportunities Focus on Health Equity and Accessibility AI in Oncology Emerging Markets Market Challenges Price Pressures and Market Access Environmental Impact and Sustainability Counterfeit Drugs Chapter 4 Regulatory Landscape Regulatory Framework Regulatory Systems for Biopharmaceuticals U.S. Europe Japan Regulatory Systems for Pharmaceuticals U.S. EU Approval Process Japan Approval Process India Approval Process Brazil Approval Process GMP Compliance Establishment Registration Drug Registration and Listing Local Agent Requirements Responsibilities of the U.S. Agent Chapter 5 Emerging Technologies and Developments Emerging Technologies Artificial Intelligence (AI) and Machine Learning (ML) Nanotechnology 3D Printing Patent Analysis Takeaways Chapter 6 Sustainability in the Pharmaceutical Drug Industry: An ESG Perspective Sustainability in the Pharmaceutical Drugs Industry Environmental Social Governance Understanding ESG Data Concluding Remarks Chapter 7 Competitive Intelligence Overview Global Market Shares of Pharmaceutical Drug Companies Strategies of Major Pharmaceutical Drug Manufacturers Distribution Networks Chapter 8 Appendix Methodology Abbreviations Sources Company Profiles Abbott AbbVie Inc. Alnylam Pharmaceuticals Inc. Amgen Inc. Argenx Astellas Pharma Inc. Astrazeneca Aurobindo Pharma Ltd. Bausch Health Companies Inc. Baxter Bayer AG Biocon Biogen Biomarin Biontech SE Boehringer Ingelheim International GmbH Bristol-Myers Squibb Co. Chugai Pharmaceutical Co. Ltd. CSL CSPC Pharmaceutical Group Ltd. Daiichi Sankyo Co. Ltd. Divi's Laboratories Ltd. Eisai Co. Ltd. F. Hoffmann-La Roche Ltd. Galderma Gilead Sciences Inc. Grifols SA GSK PLC H. Lundbeck A/S Incyte Jazz Pharmaceuticals Inc. Johnson & Johnson Services Inc. Les Laboratoires Servier Lilly Merck & Co. Inc. Merck KGaA Moderna Inc. Neurocrine Biosciences Inc. Novartis AG Novo Nordisk A/S Otsuka Holdings Co. Ltd. Pfizer Inc. Regeneron Pharmaceuticals Inc. Sanofi Sino Biopharmaceutical Co. Ltd. Sun Pharmaceutical Industries Ltd. Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd. Vertex Pharmaceuticals Inc. Viatris Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Business
- Yahoo
Shareholders Will Be Pleased With The Quality of Pfizer's (NYSE:PFE) Earnings
When companies post strong earnings, the stock generally performs well, just like Pfizer Inc.'s (NYSE:PFE) stock has recently. Our analysis found some more factors that we think are good for shareholders. Our free stock report includes 3 warning signs investors should be aware of before investing in Pfizer. Read for free now. To properly understand Pfizer's profit results, we need to consider the US$7.0b expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's hardly a surprise given these line items are considered unusual. In the twelve months to March 2025, Pfizer had a big unusual items expense. As a result, we can surmise that the unusual items made its statutory profit significantly weaker than it would otherwise be. That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates. As we discussed above, we think the significant unusual expense will make Pfizer's statutory profit lower than it would otherwise have been. Based on this observation, we consider it possible that Pfizer's statutory profit actually understates its earnings potential! And one can definitely find a positive in the fact that it made a profit this year, despite losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. At Simply Wall St, we found 3 warning signs for Pfizer and we think they deserve your attention. This note has only looked at a single factor that sheds light on the nature of Pfizer's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
08-05-2025
- Business
- Yahoo
Women's Health Therapeutics Market Poised for Growth: Innovation, Investment and Global Impact
"BCC Research presents an in-depth analysis of how innovations, market dynamics, regional trends and ESG strategies are shaping the $81.2 billion women's health therapeutics market." BOSTON, May 8, 2025 /PRNewswire/ -- As global awareness of gender-specific medicine continues to rise, the women's health therapeutics market is entering a pivotal era of innovation and investment. Leading pharmaceutical players—such as Pfizer Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd.—are accelerating the development of targeted therapies to address conditions like breast cancer, menopause, PCOS and endometriosis. According to the report, growing emphasis on personalized medicine and biologics is reshaping corporate strategies, especially as North America leads global expansion and emerging technologies unlock new care models. While the market is projected to grow at a CAGR of 5.7% from 2024 to 2029, stakeholders must navigate regulatory hurdles and rising treatment costs to capture long-term value. This shift marks a profound transformation in how biotech investors, manufacturers, and healthcare providers approach women's health—transitioning it from underserved to a global priority. Market Overview: Key Insights and ForecastBCC Research's latest report on Women's Health Therapeutics: Technologies and Global Markets provides a comprehensive breakdown of market trends, investment dynamics, and therapeutic pipelines. The global market is expected to grow from $61.5 billion in 2024 to $81.2 billion by 2029, reflecting a shift toward biologics, hormonal therapies, and digital health solutions. The report offers strategic insights across key areas, including segmentation analysis, competitive intelligence, regulatory structures, ESG perspectives and emerging technologies that are reshaping the global women's health therapeutics industry. Market Leadership in Transition The women's health therapeutics market is undergoing significant transformation, driven by an aging female population and rising demand for condition-specific treatment options. Companies like Pfizer, Eli Lilly and Novartis AG are actively investing in late-stage R&D for areas such as menopause and postmenopausal osteoporosis (Chapter 5, Pipeline Assessment and Analysis; Chapter 8, Competitive Landscape). The breast cancer segment remains the most dominant, supported by increasing incidence rates and continued innovation in monoclonal antibodies and biosimilars (Chapter 7, Market Segmentation Analysis). Emerging Technologies and Investment Trends As outlined in Chapter 4 (Emerging Technologies), cutting-edge innovations such as gene therapy, CRISPR, and transdermal delivery platforms are opening doors for safer, more personalized treatments. These technologies are also enabling commercialization models in digital health and remote care—areas expected to see strong growth. North America leads regional expansion, projected to grow from $28.4 billion in 2024 to $37.4 billion by 2029 at a 5.6% CAGR (Chapter 7, Regional Analysis). This growth is fueled by robust R&D infrastructure, regulatory support and access to biologics and HRT. Meanwhile, Europe and the Asia-Pacific region present significant opportunities as healthcare systems modernize and policies evolve. Pipeline Assessment and Analysis Chapter 5 details how companies are diversifying pipelines across hormonal, non-hormonal and biologic therapies aimed at improving efficacy and minimizing side effects. Roche, in particular, has solidified its leadership in the U.S. market through its strong presence in the breast cancer, postmenopausal osteoporosis, menopause, endometriosis, and PCOS segments. (Chapter 8, Competitive Landscape) Regulatory and Access Challenges Chapter 3 (Market Dynamics) highlights persistent barriers such as high treatment costs and slow regulatory pathways, particularly in low-income regions where access to diagnostics and therapies remains limited. Chapter 6 (Regulatory Structure) explains how regional discrepancies in clinical trial approvals and intellectual property rules impact time-to-market and ROI projections for drug developers. Strategic Outlook: The Road Ahead According to Chapter 9 (ESG Perspective), the industry is increasingly aligning with environmental, social and governance (ESG) goals—focusing on inclusivity in clinical trials, sustainable manufacturing, and broader access to care. Firms integrating ESG into product pipelines and geographic strategies are well-positioned to win both market share and investor confidence. With rising awareness, policy support and a wave of therapeutic innovation, women's health is becoming central to the future of equitable, personalized healthcare. The next five years will be critical for companies to lead, adapt and innovate in this fast-evolving space. Report Synopsis Report Metric Details Base year considered 2023 Forecast period considered 2024-2029 Base year market size $58.3 billion Market size forecast $81.2 billion Growth rate CAGR of 5.7% for the forecast period of 2024-2029 Segments covered Women's Health Disorders, and Region Regions covered North America, Europe, Asia-Pacific, and the Rest of the World (RoW) Countries covered U.S., Canada, Mexico, France, Germany, the U.K., Italy, Spain, Japan, India, Australia, South Korea and China Market drivers • Rising geriatric population of women. • Rising awareness of and accessibility to healthcare and advanced therapeutic products. • Advances in personalized medicine. • Emerging markets. Additional Insights: The women's health therapeutics market is expanding rapidly, driven by increasing awareness, technological advancements, and increased attention to under-addressed conditions such as menopause, endometriosis, and polycystic ovary syndrome (PCOS). Governments and healthcare organizations around the world are implementing initiatives to enhance access to women's health treatments, including funding programs for maternal care, reproductive health, and breast cancer screening. Market leaders include: AbbVie Inc. Amgen Inc. Asahi Kasei Corp. AstraZeneca Bayer AG Bristol-Myers Squibb Co. Eisai Co. Ltd. F. Hoffmann-La Roche Ltd. Johnson & Johnson Services Inc. Lilly Merck & Co. Inc. Novartis AG Novo Nordisk A/S Pfizer Inc. Teva Pharmaceutical Industries Ltd. Navigate Uncertainty with Confidence In times of rapid change and uncertainty, having the right insights can make all the difference. At BCC Research, we're here to support innovation and help you stay ahead. Our custom research reports provide a comprehensive, 360-degree view of your market landscape—providing you with the clarity you need to make informed decisions. We believe that timely, expert market intelligence should be accessible to all. That's why, for a limited time, we're offering 30% off the price of any BCC Research report to help more organizations gain access to our latest data and insights. Get your copy of the report directly from BCC Research. To request more information or complete your purchase, connect with us at info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact Us Corporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USA Email: info@ Phone: +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo - View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
07-05-2025
- Business
- Yahoo
Mercer County looking at paying bigger jail bills
princeton – Seeing the daily cost of housing an inmate jump by $12 is leading to a special Mercer County Commission meeting Thursday about how to keep the county's regional jail bill paid until the fiscal year ends this July. The Mercer County Commission's special meeting starts at 2 p.m., Thursday at the county courthouse. The commission will discuss the regional jail bill for April 2025 and the Glenwood Lake Dredging Project. Last March, the West Virginia Regional Jail system was holding 163 Mercer County inmates. In April, there were 129 county inmates. The daily cost of keeping each inmate started growing in April when an increase the Legislature passed in March 2023 went into effect, County Commission President Bill Archer said Tuesday. 'Because of the increases, the jail bill has gone up astronomically,' Archer said. In March, the county's jail bill was $127,474.81. By April, it had grown to $146,985.60, according to county records. 'So it's just been climbing constantly and we're having to look at some of the potential other funds in order to be able to do it,' Archer said. Archer flipped through an inmates list. 'It's all the people from around this area whether it was inmates taken in from the state police, from the county deputies and both the cities of Princeton and Bluefield,' he said. 'The county is responsible for those inmates. I understand it's a major increase but they (regional jail authority) are having space challenges there and that kind of thing and, of course, they went through that lawsuit of the inmates against the regional jail system.' The special meeting is for discussing how the county commission can pay the jail bill until the current fiscal year ends on June 30. Archer said a recent settlement in an antitrust lawsuit between West Virginia and a drug manufacturer could provide extra funding. Mercer County was among the counties and municipalities across West Virginia that shared nearly $3.5 million raised as part of a settlement agreement involving the cholesterol drug Lipitor, according to West Virginia Attorney General J.B. McCuskey announced May 1. The settlement was from an antitrust lawsuit against Pfizer Inc. and related companies and Ranbaxy Inc. The lawsuit alleged the two companies conspired to delay the introduction onto the market of a cheaper generic version of Lipitor for 20 months. Lipitor's original patent expired on March 24, 2010. Mercer County received $50,000 from the settlement. Raleigh County also received $50,000 from the settlement while McDowell County and Fayette County each received $30,000. Unlike funds raised by West Virginia's settlements with opioid manufacturers, counties have flexibility with how they spend their Pfizer settlements, Archer said. This means the funds could help cover the county's jail expenses for the rest of the fiscal year. Adjusting the county's budget is on the commission's May 13 meeting agenda. The budget is still being compiled Tuesday. 'It's really difficult times and that kind of hit us,' Archer said about the jail bill. 'That's expected, but unexpected in how draconian it is. Thankfully we've got good people in the county clerk's office who are constantly looking at the funds we have coming in and constantly looking at ways we can make adjustments so we can meet our requirements. It's a day-to-day right now. We're having to clamp down on stuff. This is a challenge; again, we'll talk about that next Tuesday.' Contact Greg Jordan at gjordan@
